ArticleFrontiers in microbiology2021
Antibacterial and Anti-biofilm Efficacy of Chinese Dragon's Blood Against
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Prevention and Treatment ofPathogens (Basel, Switzerland) · 2026Review
- Baohuoside I targets SaeR as an antivirulence strategy to disrupt MRSA biofilm formation and pathogenicity.NPJ biofilms and microbiomes · 2025Article
- Anti-Virulence Efficacy of Chinese Dragon's Blood AgainstInfection and drug resistance · 2025Article
- Effects ofFoods (Basel, Switzerland) · 2024Article
- Transformation of Natural Resin Resina Draconis to 3D Functionalized Fibrous Scaffolds for Efficient Chronic Wound Healing.Advanced healthcare materials · 2024Article
- GlmS plays a key role in the virulence factor expression and biofilm formation ability ofVirulence · 2024Article
- Co-Delivery ofPharmaceutics · 2024Article
- Dragon's Blood-Loaded Mesoporous Silica Nanoparticles for Rapid Hemostasis and Antibacterial Activity.Molecules (Basel, Switzerland) · 2024Article
- Metabolomics and quantitative analysis to determine differences in the geographical origins and species of Chinese dragon's blood.Frontiers in plant science · 2024Article
- Repurposed Fenoprofen Targeting SaeR AttenuatesACS central science · 2023Article
- Pharmacodynamics of Dracorhodin Perchlorate and Its Inflammation-Targeting Emulsion Gel for Wound Healing.Gels (Basel, Switzerland) · 2022Article
- Biofilm-Associated Agr and Sar Quorum Sensing Systems ofACS omega · 2022Article
- Antimicrobial Peptide L18R Displays a Modulating Action against Inter-Kingdom Biofilms in the Lubbock Chronic Wound Biofilm Model.Microorganisms · 2021Article
- Enhanced antibacterial effect of blue light in combination with an Amazonian tree sap (Croton lechleri).Photochemistry and photobiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chinese dragon's blood (CDB), a characteristic red resin, is an important traditional Chinese medicine (TCM), and empiric therapy of infected wounds with CDB is performed in clinical settings. For the first time, we herein report the antibacterial and anti-biofilm efficacy of CDB against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.